Effects of selective serotonin reuptake inhibition on neural activity related to risky decisions and monetary rewards in healthy males

NeuroImage

Volumn 99, Issue , 2014, Pages 434-442

  Macoveanu, Julian ^a,b   Fisher, Patrick M ^b,c   Haahr, Mette E ^b,c   Frokjaer, Vibe G ^b,c   Knudsen, Gitte M ^b,c   Siebner, Hartwig R ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Center for Integrated Molecular Brain Imaging   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Decision making; FMRI; Orbitofrontal cortex; Raphe; Reward; SSRI

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DECISION MAKING; DRUG BLOOD LEVEL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GAMBLING; HIGH RISK BEHAVIOR; HUMAN; HUMAN EXPERIMENT; LONG TERM CARE; MALE; MESENCEPHALON; MONEY; NERVE POTENTIAL; NERVE PROJECTION; NORMAL HUMAN; ORBITAL CORTEX; PRIORITY JOURNAL; RAPHE NUCLEUS; REWARD; SEROTONINERGIC SYSTEM; TASK PERFORMANCE; BLOOD; BRAIN; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; BRAIN; DECISION MAKING; DEPRESSION; DOUBLE-BLIND METHOD; FLUOXETINE; GAMBLING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; REWARD; RISK-TAKING; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84903641610     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.05.040     Document Type: Article

References (49)

1. Abler B., Seeringer A., Hartmann A., Grön G., Metzger C., Walter M., Stingl J. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology 2011, 36:1837-1847. 10.1038/npp.2011.66.
2. Baldwin D.S., Stein D.J., Dolberg O.T., Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum. Psychopharmacol. 2009, 24:269-275. 10.1002/hup.1019.
3. Benmansour S., Owens W.A., Cecchi M., Morilak D.A., Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 2002, 22:6766-6772. (doi:20026626).
4. Best J., Nijhout H.F., Reed M. Bursts and the efficacy of selective serotonin reuptake inhibitors. Pharmacopsychiatry 2011, 44(Suppl. 1):S76-S83. 10.1055/s-0031-1273697.
5. Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 1993, 16:387-400.
6. Byrnes J.P., Miller D.C., Schafer W.D. Gender differences in risk taking: a meta-analysis. Psychol. Bull. 1999, 125:367-383.
7. Charlier C., Pinto E., Ansseau M., Plomteux G. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum. Psychopharmacol. 2000, 15:453-459. 10.1002/1099-1077(200008)15:6<453::AID-HUP228>3.0.CO;2-F.
8. Cosgrove K.P., Mazure C.M., Staley J.K. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol. Psychiatry 2007, 62:847-855. 10.1016/j.biopsych.2007.03.001.
9. Deichmann R., Gottfried J.A., Hutton C., Turner R. Optimized EPI for fMRI studies of the orbitofrontal cortex. Neuroimage 2003, 19:430-441.
10. Derogatis L.R. Symptom Checklist-90-R (SCL-90-R): Administration, Scoring, and Procedures Manual 1994, National Computer Systems, Minneapolis, Minn. 3rd ed.
11. Firk C., Siep N., Markus C.R. Serotonin transporter genotype modulates cognitive reappraisal of negative emotions: a functional magnetic resonance imaging study. Soc. Cogn. Affect. Neurosci. 2013, 8:247-258. 10.1093/scan/nsr091.
12. Forsell Y. The Major Depression Inventory versus Schedules for Clinical Assessment in Neuropsychiatry in a population sample. Soc. Psychiatry Psychiatr. Epidemiol. 2005, 40:209-213. 10.1007/s00127-005-0876-3.
13. Glover G.H., Li T.Q., Ress D. Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR. Magn. Reson. Med. 2000, 44:162-167.
14. Haahr M.E., Fisher P.M., Jensen C.G., Frokjaer V.G., Mahon B.M., Madsen K., Baaré W.F.C., Lehel S., Norremolle A., Rabiner E.A., Knudsen G.M. Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. Mol. Psychiatry. 2014, 19:427-432. 10.1038/mp.2013.147.
15. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998, 18:10150-10156.
16. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297(80-):400-403. 10.1126/science.1071829.
17. Hayes D.J., Greenshaw A.J. 5-HT receptors and reward-related behaviour: a review. Neurosci. Biobehav. Rev. 2011, 35:1419-1449. 10.1016/j.neubiorev.2011.03.005.
18. Hornung J.-P. The human raphe nuclei and the serotonergic system. J. Chem. Neuroanat. 2003, 26:331-343.
19. Hu X.-Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 2006, 78:815-826. 10.1086/503850.
20. Jannuzzi G., Gatti G., Magni P., Spina E., Pacifici R., Zuccaro P., Torta R., Guarneri L., Perucca E. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther. Drug Monit. 2002, 24:616-627.
21. Kranz G.S., Hahn A., Savli M., Lanzenberger R. Challenges in the differentiation of midbrain raphe nuclei in neuroimaging research. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2000. 10.1073/pnas.1206247109.
22. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 1995, 274:866-876.
23. Kuhnen C.M., Knutson B. The neural basis of financial risk taking. Neuron 2005, 47:763-770.
24. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Müller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274(80-):1527-1531.
25. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
26. Liu X., Powell D.K., Wang H., Gold B.T., Corbly C.R., Joseph J.E. Functional dissociation in frontal and striatal areas for processing of positive and negative reward information. J. Neurosci. 2007, 27:4587-4597. 10.1523/JNEUROSCI.5227-06.2007.
27. Lund T.E., Madsen K.H., Sidaros K., Luo W.-L., Nichols T.E. Non-white noise in fMRI: does modelling have an impact?. Neuroimage 2006, 29:54-66. 10.1016/j.neuroimage.2005.07.005.
28. Macoveanu J., Rowe J.B., Hornboll B., Elliott R., Paulson O.B., Knudsen G.M., Siebner H.R. Playing it safe but losing anyway-serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. Eur. Neuropsychopharmacol. 2013, 23:919-930. 10.1016/j.euroneuro.2012.09.006.
29. Macoveanu J., Rowe J.B., Hornboll B., Elliott R., Paulson O.B., Knudsen G.M., Siebner H.R. Serotonin 2A receptors contribute to the regulation of risk-averse decisions. Neuroimage 2013, 83:35-44. 10.1016/j.neuroimage.2013.06.063.
30. Macoveanu J., Knorr U., Skimminge A., Søndergaard M.G., Jørgensen A., Fauerholdt-Jepsen M., Paulson O.B., Knudsen G.M., Siebner H.R., Kessing L.V. Altered reward processing in the orbitofrontal cortex and hippocampus in healthy first-degree relatives of patients with depression. Psychol. Med. 2014, 44:1183-1195. 10.1017/S0033291713001815.
31. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19:1233-1239.
32. McCabe C., Mishor Z., Cowen P.J., Harmer C.J. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol. Psychiatry 2010, 67:439-445. 10.1016/j.biopsych.2009.11.001.
33. McDevitt R.A., Neumaier J.F. Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. J. Chem. Neuroanat. 2011, 41:234-246. 10.1016/j.jchemneu.2011.05.001.
34. Moses-Kolko E.L., Price J.C., Shah N., Berga S., Sereika S.M., Fisher P.M., Coleman R., Becker C., Mason N.S., Loucks T., Meltzer C.C. Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology 2011, 36:2729-2740. 10.1038/npp.2011.163.
35. Nakamura K. The role of the dorsal raphé nucleus in reward-seeking behavior. Front. Integr. Neurosci. 2013, 7:60. 10.3389/fnint.2013.00060.
36. Nutt D.J., Forshall S., Bell C., Rich A., Sandford J., Nash J., Argyropoulos S. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 1999, 9(Suppl. 3):S81-S86.
37. Opbroek A., Delgado P.L., Laukes C., McGahuey C., Katsanis J., Moreno F.A., Manber R. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?. Int. J. Neuropsychopharmacol. 2002, 5:147-151. 10.1017/S1461145702002870.
38. Paulmann S., Seifert S., Kotz S.A. Orbito-frontal lesions cause impairment during late but not early emotional prosodic processing. Soc. Neurosci. 2010, 5:59-75. 10.1080/17470910903135668.
39. Price J., Cole V., Goodwin G.M. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br. J. Psychiatry 2009, 195:211-217. 10.1192/bjp.bp.108.051110.
40. Ranade S.P., Mainen Z.F. Transient firing of dorsal raphe neurons encodes diverse and specific sensory, motor, and reward events. J. Neurophysiol. 2009, 102:3026-3037. 10.1152/jn.00507.2009.
41. Risch S.C., Nemeroff C.B. Neurochemical alterations of serotonergic neuronal systems in depression. J. Clin. Psychiatry 1992, 53:3-7. (Suppl.).
42. Rogers R.D., Tunbridge E.M., Bhagwagar Z., Drevets W.C., Sahakian B.J., Carter C.S. Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology 2003, 28:153-162. 10.1038/sj.npp.1300001.
43. Sharp T., Boothman L., Raley J., Quérée P. Important messages in the "post": recent discoveries in 5-HT neurone feedback control. Trends Pharmacol. Sci. 2007, 28:629-636. 10.1016/j.tips.2007.10.009.
44. Smoski M.J., Rittenberg A., Dichter G.S. Major depressive disorder is characterized by greater reward network activation to monetary than pleasant image rewards. Psychiatry Res. 2011, 194:263-270. 10.1016/j.pscychresns.2011.06.012.
45. Taylor S.F., Martis B., Fitzgerald K.D., Welsh R.C., Abelson J.L., Liberzon I., Himle J.A., Gehring W.J. Medial frontal cortex activity and loss-related responses to errors. J. Neurosci. 2006, 26:4063-4070. 10.1523/JNEUROSCI.4709-05.2006.
46. Tobler P.N., O'Doherty J.P., Dolan R.J., Schultz W. Reward value coding distinct from risk attitude-related uncertainty coding in human reward systems. J. Neurophysiol. 2007, 97:1621-1632. 10.1152/jn.00745.2006.
47. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289. 10.1006/nimg.2001.0978.
48. Watts R., Spencer E.P., Wood M. Quantitative analysis of multiple psychotherapeutic drugs in human serum using UPLC/MS/MS. Quant. Anal. Mult. Psychother. drugs Hum. serum using UPLC/MS/MS 2008.
49. Wu C.C., Sacchet M.D., Knutson B. Toward an affective neuroscience account of financial risk taking. Front. Neurosci. 2012, 6:159. 10.3389/fnins.2012.00159.